Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERBRAIN: T-DXd + SRS in HER2+ Metastatic Breast Cancer with Brain Metastases
NCT07905313Phase 2Not yet recruiting
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Start
- May 2027
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by Azienda Ospedaliero-Universitaria Careggi. Planned start May 2027; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07905313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07905313.